Development of Novel Chitosan Microcapsules for Pulmonary Delivery of Dapsone: Characterization, Aerosol Performance, and In Vivo Toxicity Evaluation

AAPS PharmSciTech

Volumn 16, Issue 5, 2015, Pages 1033-1040

  Ortiz, Manoel ^a   Jornada, Denise Soledade ^a   Pohlmann, Adriana Raffin ^a   Guterres, Sílvia Stanisçuaski ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

dapsone; dry powders inhalers; in vivo toxicity; microparticles; pulmonary drug delivery

Indexed keywords

CHITOSAN; DAPSONE; AEROSOL; ANTIINFECTIVE AGENT; DELAYED RELEASE FORMULATION; DRUG CARRIER; MICROCAPSULE; POWDER;

AEROSOL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; GEOMETRY; IN VITRO STUDY; IN VIVO STUDY; LUNG PARENCHYMA; MALE; MICROCAPSULE; MICROENCAPSULATION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; SCANNING ELECTRON MICROSCOPY; SUSTAINED DRUG RELEASE; ANIMAL; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG FORMULATION; INHALATIONAL DRUG ADMINISTRATION; LUNG; METABOLISM; POWDER; RESPIRATORY FUNCTION; SOLUBILITY; ULTRASTRUCTURE; WISTAR RAT;

ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; ANTI-BACTERIAL AGENTS; CAPSULES; CHITOSAN; DAPSONE; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG COMPOUNDING; LUNG; MALE; MICROSCOPY, ELECTRON, SCANNING; PARTICLE SIZE; POWDERS; RATS, WISTAR; RESPIRATORY TRACT ABSORPTION; SOLUBILITY;

EID: 84944516307     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-015-0283-3     Document Type: Article

References (40)

1. Gutierrez S, Morilla R, Leon JA, Martin-Garrido I, Rivero L, Friaza V, et al. High prevalence of Pneumocystis jiroveci colonization among young HIV-infected patients. J Adolesc Health. 2011;48(1):103–5.
2. Bennett NJGSAR, Burton F, McLean, J C, Murray C, Schreibman T S, Rigsby M. Pneumocystis (carinii) jiroveci pneumonia. 2010. http://www.patient.co.uk/doctor/pneumocystis-jirovecii-pneumonia
3. Fishman JA. Treatment of infection due to Pneumocystis carinii. Antimicrob Agents Chemother. 1998;42(6):1309–14.
4. Kovacs JA, Gill VJ, Meshnick S, Masur H. New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia. JAMA-J Am Med Assoc [Article]. 2001;286(19):2450–60.
5. Ramesh M, Chandrasekar PH. Effective alternates to trimethoprim-sulfamethoxazole as antimicrobial prophylaxis in stem cell recipients: are there any? Pediatr Transplant. 2008;12(8):823–6.
6. Wolf R, Tuzun B, Tuzun Y. Dapsone: unapproved uses or indications. Clin Dermatol. 2000;18(1):37–53.
7. Blum RN, Miller LA, Gaggini LC, Cohn DL. Comparative trial of dapsone versus trimethoprim/sulfamethoxazole for primary prophylaxis of Pneumocystis carinii pneumonia. J Acquir Immune Defic Syndr. 1992;5(4):341–7.
8. Coleman MD. Dapsone-mediated agranulocytosis: risks, possible mechanisms and prevention. Toxicology. 2001;162(1):53–60.
9. Reddy C, Kannan G, Vasantha J, Kousalya K, Rani N, Thennarasu P, et al. Drug usage evaluation of dapsone. Indian J Pharm Sci. 2009;71(4):456–60.
10. Chougule M, Padhi B, Misra A. Development of spray dried liposomal dry powder inhaler of dapsone. AAPS PharmSciTech. 2008;9(1):47–53.
11. Ravi Kumar MN. Nano and microparticles as controlled drug delivery devices. J Pharm Pharm Sci. 2000;3(2):234–58.
12. Jyothi NV, Prasanna PM, Sakarkar SN, Prabha KS, Ramaiah PS, Srawan GY. Microencapsulation techniques, factors influencing encapsulation efficiency. J Microencapsul. 2010;27(3):187–97.
13. Oneda F, Re MI. The effect of formulation variables on the dissolution and physical properties of spray-dried microspheres containing organic salts. Powder Technol. 2003;130(1):377–84.
14. El-Gibaly I. Development and in vitro evaluation of novel floating chitosan microcapsules for oral use: comparison with non-floating chitosan microspheres. Int J Pharm. 2002;249(1–2):7–21.
15. Frijlink HW, De Boer AH. Dry powder inhalers for pulmonary drug delivery. Expert Opin Drug Deliv. 2004;1(1):67–86.
16. Grenha A, Seijo B, Remuñán-López C. Microencapsulated chitosan nanoparticles for lung protein delivery. Eur J Pharm Sci. 2005;25(4–5):427–37.
17. Cruz L, Fattal E, Tasso L, Freitas GC, Carregaro AB, Guterres SS, et al. Formulation and in vivo evaluation of sodium alendronate spray-dried microparticles intended for lung delivery. J Control Release [Article]. 2011;152(3):370–5.
18. Pilcer G, Amighi K. Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm. 2010;392(1–2):1–19.
19. D’Addio SM, Chan JG, Kwok PC, Prud’homme RK, Chan HK. Constant size, variable density aerosol particles by ultrasonic spray freeze drying. Int J Pharm. 2012;427(2):185–91.
20. Zhang X, Ma Y, Zhang L, Zhu J, Jin F. The development of a novel dry powder inhaler. Int J Pharm. 2012;431(1–2):45–52.
21. de Boer AH, Wissink J, Hagedoorn P, Heskamp I, de Kruijf W, Bunder R, et al. In vitro performance testing of the novel Medspray wet aerosol inhaler based on the principle of Rayleigh break-up. Pharm Res. 2008;25(5):1186–92.
22. Xu L, Dong XW, Shen LL, Li FF, Jiang JX, Cao R, et al. Simvastatin delivery via inhalation attenuates airway inflammation in a murine model of asthma. Int Immunopharmacol. 2012;12(4):556–64.
23. Mukhopadhyay P, Mishra R, Rana D, Kundu PP. Strategies for effective oral insulin delivery with modified chitosan nanoparticles: a review. Prog Polym Sci. 2012;37(11):1457–75.
24. Zhang J, Zhu X, Jin Y, Shan W, Huang Y. Mechanism study of cellular uptake and tight junction opening mediated by goblet cell-specific trimethyl chitosan nanoparticles. Mol Pharm. 2014;11(5):1520–32.
25. Price N, Newman B. Demonstration of the principles of enzyme-catalysed reactions using alkaline phosphatase. Biochem Mol Biol Educ. 2000;28(4):207–2010.
26. Vargas M, Albors A, Chiralt A, González-Martínez C. Characterization of chitosan–oleic acid composite films. Food Hydrocolloids. 2009;23(2):536–47.
27. Wang H-C, John W. Particle density correction for the aerodynamic particle sizer. Aerosol Sci Technol. 1987;6(2):191–8.
28. Washington C. Drug release from microdisperse systems: a critical review. Int J Pharm. 1990;58(1):1–12.
29. Babson A, Philips GE. A rapid colorimetric assay for serum lactic dehydrogenase. Clin Chemica Acta. 1965;12:265–75.
30. Hussain A, Majumder QH, Ahsan F. Inhaled insulin is better absorbed when administered as a dry powder compared to solution in the presence or absence of alkylglycosides. Pharm Res. 2006;23(1):138–47.
31. Layne E. Total protein-modified according to Layne, E., spectropho-tometric and turbidimetric methods for measuring proteins. II. Protein estimation with the Folin-Ciocalteu reagent. Methods Enzimol. 1957;3:447–54.
32. Learoyd TP, Burrows JL, French E, Seville PC. Sustained delivery by leucine-modified chitosan spray-dried respirable powders. Int J Pharm. 2009;372(1–2):97–104.
33. Okamoto H, Shiraki K, Yasuda R, Danjo K, Watanabe Y. Chitosan-interferon-beta gene complex powder for inhalation treatment of lung metastasis in mice. J Control Release. 2011;150(2):187–95.
34. Vehring R, Foss WR, Lechuga-Ballesteros D. Particle formation in spray drying. J Aerosol Sci. 2007;38(7):728–46.
35. Pilcer G, Wauthoz N, Amighi K. Lactose characteristics and the generation of the aerosol. Adv Drug Deliv Rev. 2012;64(3):233–56.
36. Li FQ, Yan C, Bi J, Lv WL, Ji RR, Chen X, et al. A novel spray-dried nanoparticles-in-microparticles system for formulating scopolamine hydrobromide into orally disintegrating tablets. Int J Nanomedicine. 2011;6:897–904.
37. Alhalaweh A, Andersson S, Velaga SP. Preparation of zolmitriptan-chitosan microparticles by spray drying for nasal delivery. Eur J Pharm Sci. 2009;38(3):206–14.
38. Aquino RP, Prota L, Auriemma G, Santoro A, Mencherini T, Colombo G, et al. Dry powder inhalers of gentamicin and leucine: formulation parameters, aerosol performance and in vitro toxicity on CuFi1 cells. Int J Pharm. 2012;426(1–2):100–7.
39. Wu P-C, Huang Y-B, Chang J-S, Tsai M-J, Tsai Y-H. Design and evaluation of sustained release microspheres of potassium chloride prepared by Eudragit®. Eur J Pharm Sci. 2003;19(2–3):115–22.
40. Henderson RF. Use of bronchoalveolar lavage to detect respiratory tract toxicity of inhaled material. Exp Toxicol Pathol. 2005;57 Suppl 1:155–9.